I assume they (Roche) have more candidates than they can handle at the moment. They will earn money if it is successfully developed due to royalties and milestones. However, does NRT really have this kind of money right now? Seems to overlap with Trilexium's target, too. I don't really understand what's going on here, and I'm confused whether this is a good thing or not.
Ann: In-licencing of Phase II-ready molecule - presentation-NRT.AX, page-3
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)